Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Healthcare utilization sits at the center of this dementia and brain health question.
Healthcare utilization data paints a sobering picture of Alzheimer’s treatment access in the United States: while new disease-modifying therapies show promise in slowing cognitive decline, the gap between diagnosis and actual treatment initiation remains alarmingly wide. Only 26% of newly-diagnosed Alzheimer’s patients fill a prescription within 90 days of diagnosis, and just 36% do so within a full year. This means nearly two-thirds of newly-diagnosed patients receive no prescription for cholinesterase inhibitors or memantine during their first year after diagnosis—a critical window when early intervention could make the most difference.
The data reveals multiple layers of access barriers that determine whether patients can actually benefit from available treatments. Insurance coverage gaps, geographic shortages of dementia specialists, medication adherence challenges, and significant racial and ethnic disparities all contribute to a fragmented treatment landscape. What should be a straightforward progression from diagnosis to treatment instead becomes a complex maze that many patients never navigate successfully.
Table of Contents
- Why Are So Many Alzheimer’s Patients Not Getting Treatment Shortly After Diagnosis?
- The Persistent Problem of Non-Adherence and Treatment Discontinuation
- How Racial and Ethnic Disparities Shape Treatment Access and Outcomes
- Geographic Location and Specialist Availability: A Fundamental Access Barrier
- The Emerging Role of Home-Based Administration and Its Limitations
- What Americans Actually Know and Believe About Alzheimer’s Treatment Options
- Global Perspective on Alzheimer’s Treatment Access and What It Reveals
- Conclusion
- Frequently Asked Questions
Why Are So Many Alzheimer’s Patients Not Getting Treatment Shortly After Diagnosis?
The treatment initiation gap begins immediately after diagnosis. When a patient receives an Alzheimer’s diagnosis, the expectation might be that they begin pharmacological treatment promptly. The data contradicts this assumption. The 36% figure for prescription filling within one year is particularly telling because it represents patients who eventually did start treatment—but only after months had passed. For those 64% who never filled a prescription in year one, the barriers were sufficient to prevent access entirely. Several factors explain this gap.
Dementia specialists, the physicians most likely to prescribe disease-modifying therapies like lecanemab or donanemab, are concentrated in certain geographic areas. An estimated 34% to 59% of people aged 65 and older live in areas with potential dementia specialist shortfalls. A patient diagnosed in a rural area might need to travel hours for specialist evaluation. Their primary care physician may feel uncomfortable prescribing these newer medications without specialist guidance, creating a bottleneck. Meanwhile, months pass. By the time a specialist appointment becomes available, the window for optimal early intervention has narrowed.
The Persistent Problem of Non-Adherence and Treatment Discontinuation
Even among patients who do initiate Alzheimer’s medication, adherence becomes the next critical hurdle. Of individuals who started treatment, 44% were non-adherent—meaning they missed doses or didn’t take medication as prescribed—and 24% discontinued treatment entirely during the year following initiation. This represents a loss of nearly 68% of treated patients to either inconsistent use or complete abandonment. Non-adherence in Alzheimer’s treatment differs from other chronic conditions because cognitive impairment itself can be a barrier.
A patient with advancing cognitive decline may forget to take their medication, confuse dosing instructions, or struggle to remember why the medication matters. Family caregivers often must manage this responsibility, adding burden to relationships already strained by dementia care. Some patients experience side effects—nausea, headaches, or injection site reactions with intravenous treatments—and lack support to manage these effectively. The limitation here is stark: even when treatment access is solved, maintaining adherence remains unresolved for the majority.
How Racial and Ethnic Disparities Shape Treatment Access and Outcomes
The utilization data exposes troubling racial disparities in both access and adherence. Non-Hispanic Black patients were significantly more likely than non-Hispanic White patients to be non-adherent to Alzheimer’s medication or to discontinue treatment entirely. This disparity compounds an already concerning epidemiological reality: Black individuals aged 50 and older are 2 to 3 times more likely than Caucasians to develop dementia. Hispanic individuals face similar elevated risk, being approximately 1.5 times more likely to develop Alzheimer’s disease and related dementias. These communities face compounded barriers.
Mistrust of medical institutions rooted in historical and ongoing discrimination affects treatment engagement. Economic barriers—including underinsurance and gaps in coverage—disproportionately impact Black and Hispanic communities. Language barriers, limited cultural competence among specialists, and geographic separation from dementia care centers all interact to reduce access. A Hispanic patient in the Midwest with newly-diagnosed Alzheimer’s faces not only the standard barriers of specialist access but also potential language mismatch and cultural disconnection from her care team. When disparities in diagnosis rates combine with disparities in treatment access, the cumulative effect is profound health inequity.
Geographic Location and Specialist Availability: A Fundamental Access Barrier
Where someone lives is increasingly a determinant of whether they can access Alzheimer’s disease-modifying therapies. The concentration of dementia specialists in academic medical centers and urban areas means that rural and underserved regions face severe gaps. The data showing that 34% to 59% of seniors live in areas with potential dementia specialist shortfalls is not abstract—it means millions of Americans cannot realistically access a neurologist or geriatric psychiatrist experienced in prescribing lecanemab or donanemab.
The trade-off is significant: telemedicine can bridge some gaps, but it cannot replace in-person amyloid PET imaging or comprehensive neuropsychological testing that often precedes treatment. A patient in rural Montana might receive a diagnosis of cognitive impairment from her primary care doctor but cannot access the specialist evaluation necessary to confirm Alzheimer’s or prescribe newer disease-modifying therapies. The option to “consult a specialist” that may seem straightforward in an urban setting becomes logistically and financially impossible for others. Some health systems are beginning to train primary care physicians to prescribe these medications, but this expansion remains inconsistent across regions.
The Emerging Role of Home-Based Administration and Its Limitations
Recent FDA approvals have introduced options that could potentially increase access: lecanemab (Leqembi) now has an FDA-approved at-home injectable formulation, allowing self-administration rather than requiring clinic visits. Additionally, donanemab (Kisunla), another disease-modifying therapy, has become available. These developments represent meaningful progress, particularly for patients in areas with limited clinic access or those with mobility limitations. However, significant limitations remain.
The at-home option still requires initial clinic-based infusions and monitoring, creating an access barrier at the crucial starting point. The FDA was expected to decide in May 2026 whether to approve initial starter doses for home use as well, which would remove this requirement. Even with at-home options available, medication costs, insurance coverage decisions, and patient awareness create additional hurdles. A patient who learns of the home-based option must still navigate insurance approval, pharmacy coordination, and training to safely self-administer. These newer administration models help some patients but do not solve the fundamental problem that two-thirds of newly-diagnosed patients never initiate treatment in the first place.
What Americans Actually Know and Believe About Alzheimer’s Treatment Options
Public awareness and patient expectations shape healthcare decisions. Approximately two-thirds of Americans are aware that new medications exist to slow Alzheimer’s progression, and most feel optimistic about future treatments. This awareness, however, does not automatically translate to access or treatment initiation. Knowledge of what treatments exist and the ability to obtain them remain separate challenges.
The gap between awareness and access is paralleled by significant insurance concerns. Approximately 44% of Americans worry that insurance will not cover future dementia care and treatment. This concern is not unfounded; insurance barriers are real obstacles to treatment initiation and adherence. A patient who knows that lecanemab might help her cognitive decline may still decline to initiate treatment if she cannot afford co-payments or if her insurance denies coverage. The worry about insurance coverage directly reflects healthcare system inequities and the uncertainty many face regarding long-term dementia care financing.
Global Perspective on Alzheimer’s Treatment Access and What It Reveals
While lecanemab and donanemab have received FDA approval in the United States and have been approved in other countries, global access remains starkly limited. In many nations, these disease-modifying therapies are available only to wealthy individuals or where public health systems have explicitly adopted coverage—a rare occurrence in many countries. This global disparity illustrates how even promising medical innovations can entrench existing inequalities.
The fact that these treatments exist but remain inaccessible to most of the world’s Alzheimer’s patients is a sobering reminder that healthcare access is fundamentally a question of economics and policy, not just medicine. Looking forward, the challenge is not primarily about developing more treatments—the pharmaceutical innovation is happening. The challenge is building healthcare systems and policies that can deliver existing treatments equitably. As more disease-modifying options potentially reach the market, the utilization gap documented in healthcare data will persist unless addressed through policy changes, insurance reform, specialist training expansion, and targeted efforts to reduce disparities.
Conclusion
Healthcare utilization data reveals that the Alzheimer’s treatment landscape is characterized by profound gaps between what is medically possible and what patients actually receive. With only 36% of newly-diagnosed patients filling prescriptions within a year and less than half of those remaining adherent, the majority of Alzheimer’s patients are not benefiting from available disease-modifying therapies.
Geographic disparities in specialist availability, insurance coverage barriers, and racial and ethnic inequities in treatment access create a system in which geography and race predict whether someone will receive treatment more reliably than clinical indication or disease severity. The path forward requires multifaceted intervention: expanding dementia specialist capacity in underserved regions, training primary care physicians to prescribe disease-modifying therapies, reforming insurance coverage policies, addressing historical barriers that affect minority communities, and ensuring that newer at-home administration options actually reach patients. Until utilization data shows that the majority of newly-diagnosed Alzheimer’s patients receive timely treatment and maintain adherence, healthcare access—not treatment availability—remains the fundamental limiting factor in the fight against Alzheimer’s disease.
Frequently Asked Questions
Why do only 26% of newly-diagnosed Alzheimer’s patients fill prescriptions within 90 days?
Multiple barriers contribute, including lack of access to dementia specialists (particularly in rural areas), primary care physicians unfamiliar with new disease-modifying therapies, insurance coverage questions, and the time required for diagnostic confirmation. Geographic shortages mean some patients cannot access the specialist evaluation needed before treatment can begin.
Is non-adherence in Alzheimer’s medication different from other chronic diseases?
Yes. Cognitive impairment itself becomes a barrier—patients may forget to take medication or require a caregiver to manage doses. Additionally, some disease-modifying therapies require intravenous infusion at clinics, creating logistical challenges. The combination of cognitive decline and complex treatment regimens makes adherence particularly challenging.
How do racial disparities affect Alzheimer’s treatment access?
Multiple overlapping factors create disparities: Black and Hispanic individuals develop Alzheimer’s at higher rates but face additional barriers including historical medical mistrust, economic constraints, language barriers, and geographic distance from specialists. Non-Hispanic Black patients show higher non-adherence and treatment discontinuation rates, reflecting both access barriers and systemic inequities in healthcare delivery.
What is the difference between lecanemab and donanemab?
Both are disease-modifying therapies that slow cognitive decline in early-stage Alzheimer’s. Lecanemab (Leqembi) was approved first and now has a home-injectable formulation available. Donanemab (Kisunla) became available more recently. Both target amyloid beta in the brain. The choice between them depends on patient factors and insurance coverage, though availability itself remains a limiting factor for most patients.
Does the at-home version of lecanemab solve access problems?
It helps some patients, particularly those with mobility limitations or who live far from clinics. However, home administration does not solve the fundamental problem of initial specialist evaluation, diagnostic confirmation, and insurance approval that must occur before treatment begins. The option benefits patients who already have access to diagnosis and specialist care.
What percentage of Americans can actually access these newer Alzheimer’s treatments?
The data suggests it is far lower than awareness rates. While two-thirds of Americans know these treatments exist, the treatment initiation rate shows that access is much more limited. Geographic specialist shortages affect 34-59% of seniors, insurance concerns affect 44% of Americans, and racial disparities significantly impact Black and Hispanic communities where disease risk is already higher.
You Might Also Like
- Team-Based Healthcare Delivery Improves Alzheimer’s Treatment Coordination
- Sleep Quality Research Links Rest Patterns to Alzheimer’s Risk
- Neuroinflammation Modulation Emerges as Key Alzheimer’s Treatment Strategy
For more, see Alzheimer’s Association — caregiving.
